Відмінності між версіями «Of Cancer published by John Wiley Sons Ltd on behalf of»

Матеріал з HistoryPedia
Перейти до: навігація, пошук
м
м
 
(не показано одну проміжну версію цього учасника)
Рядок 1: Рядок 1:
−
Kaplan eier survival curves illustrating differences in time to relapse (left panels) and disease-specific survival (right panels) after liver surgery for metastatic colorectal cancer [https://www.medchemexpress.com/fosamprenavir-calcium-salt.html GW433908G web] Comparing patients harboring no mutations to patients harboring intraindividual mutation heterogeneity across either KRAS, BRAF, TP53 or PI3K and patients revealing at least one homogenous but no heterogeneous mutation in either gene (a). double wt) [https://www.medchemexpress.com/Ganetespib.html STA-9090 manufacturer] Chemotherapy1 1.08 0.93 1.55 2.00 1.73 0.92 1.12 2.34 0.39 95  CI (0.71, 1.65) (0.62, 1.40) (0.97, 2.48) (1.21, 3.29) (1.11, 2.68) (0.61,1.42) (0.63, 1.97) (1.50, 3.66) (0.23, 0.64) p values 0.720 0.726 0.064 0.007 0.015 0.720 0.700 [https://dx.doi.org/10.1186/1479-5868-9-35 title= 1479-5868-9-35] patients harboring a homogeneous mutation in at least one gene across all metastatic deposits and with no heterogeneous mutation and (iii) patients with no mutations across either gene. Comparing all three groups, univariate analysis revealed asignificant different TTR (median of 4 vs. 5 vs. 15 months, p [https://dx.doi.org/10.1002/ejsp.2064 title= ejsp.2064] 58 months, p 65 years) Sex (male vs. female) Nodal status of primary (N1 vs. N0) Synchronous vs. metachronous mets.
+
Similar analyses comparing patients harboring no mutations, heterogeneous or [http://hnbkgy.com/comment/html/?201520.html Patterns develop into conscious and can be worked on. Awareness of oneself] homogeneous mutations in either KRAS or BRAF without attention to TP53 or PI3K status (b). 4b).Multivariate analysesAs KRAS and BRAF mutations were mutually exclusive, these parameters (BRAF or KRAS mutation vs. wild-type status forC Int. J. Cancer: 139, 647?56 (2016) V 2016 The Authors International Journal of Cancer published by John Wiley  Sons Ltd on behalf of Union for International Cancer ControlMolecular Cancer BiologyMutations and heterogeneity in colorectal liver metastasesTable 2. Results from Cox regression for all patients (n 5 151) Time to relapse (TTR) HR Age ( 65 years) Sex (male vs. female) Nodal status of primary (N1 vs. N0) Synchronous vs. metachronous mets. Multiple vs. single mets. TP53 mutations PIK3CA mutations KRAS or BRAF mutations (mut vs. double wt) Chemotherapy1 1.08 0.93 1.55 2.00 1.73 0.92 1.12 2.34 0.39 95  CI (0.71, 1.65) (0.62, 1.40) (0.97, 2.48) (1.21, 3.29) (1.11, 2.68) (0.61,1.42) (0.63, 1.97) (1.50, 3.66) (0.23, 0.64) p values 0.720 0.726 0.064 0.007 0.015 0.720 0.700 [https://dx.doi.org/10.1186/1479-5868-9-35 title= 1479-5868-9-35] patients harboring a homogeneous mutation in at least one gene across all metastatic deposits and with no heterogeneous mutation and (iii) patients with no mutations across either gene. Comparing all three groups, univariate analysis revealed asignificant different TTR (median of 4 vs. 5 vs. 15 months, p [https://dx.doi.org/10.1002/ejsp.2064 title= ejsp.2064] 58 months, p

Поточна версія на 18:51, 8 грудня 2017

Similar analyses comparing patients harboring no mutations, heterogeneous or Patterns develop into conscious and can be worked on. Awareness of oneself homogeneous mutations in either KRAS or BRAF without attention to TP53 or PI3K status (b). 4b).Multivariate analysesAs KRAS and BRAF mutations were mutually exclusive, these parameters (BRAF or KRAS mutation vs. wild-type status forC Int. J. Cancer: 139, 647?56 (2016) V 2016 The Authors International Journal of Cancer published by John Wiley Sons Ltd on behalf of Union for International Cancer ControlMolecular Cancer BiologyMutations and heterogeneity in colorectal liver metastasesTable 2. Results from Cox regression for all patients (n 5 151) Time to relapse (TTR) HR Age ( 65 years) Sex (male vs. female) Nodal status of primary (N1 vs. N0) Synchronous vs. metachronous mets. Multiple vs. single mets. TP53 mutations PIK3CA mutations KRAS or BRAF mutations (mut vs. double wt) Chemotherapy1 1.08 0.93 1.55 2.00 1.73 0.92 1.12 2.34 0.39 95 CI (0.71, 1.65) (0.62, 1.40) (0.97, 2.48) (1.21, 3.29) (1.11, 2.68) (0.61,1.42) (0.63, 1.97) (1.50, 3.66) (0.23, 0.64) p values 0.720 0.726 0.064 0.007 0.015 0.720 0.700 title= 1479-5868-9-35 patients harboring a homogeneous mutation in at least one gene across all metastatic deposits and with no heterogeneous mutation and (iii) patients with no mutations across either gene. Comparing all three groups, univariate analysis revealed asignificant different TTR (median of 4 vs. 5 vs. 15 months, p title= ejsp.2064 58 months, p

Отримано з http://istoriya.soippo.edu.ua/index.php?title=Of_Cancer_published_by_John_Wiley_Sons_Ltd_on_behalf_of&oldid=262581